Mackie cut shares of Spectral Medical Inc (TSE:EDT) from a speculative buy rating to a sell rating in a research note published on Monday morning.

Several other research firms have also recently commented on EDT. Cormark cut Spectral Medical from a buy rating to a reduce rating in a report on Monday. GMP Securities reaffirmed a speculative buy rating on shares of Spectral Medical in a report on Wednesday, September 14th.

Shares of Spectral Medical (TSE:EDT) opened at 0.24 on Monday. Spectral Medical has a 1-year low of $0.18 and a 1-year high of $2.07. The company’s market cap is $49.62 million. The stock has a 50 day moving average price of $1.27 and a 200-day moving average price of $1.02.

About Spectral Medical

Spectral Medical Inc, formerly Spectral Diagnostics Inc, is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents.

Receive News & Stock Ratings for Spectral Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical Inc and related stocks with our FREE daily email newsletter.